Sun Pharma's IL-23 inhibitor tildrakizumab gains a psoriatic arthritis indication; the announcement cited no phase 3 efficacy figures.
|Articles|August 9, 2018
Take Our Survey for a $200 Discount on This Year's CBI Product Launch Summit
Author(s)Pharmaceutical Executive
Advertisement
CBI's 4th Bio/Pharmaceutical Product Launch Summit runs in Cambridge, MA, on September 25-26. This year's speakers-including Jasmine Daniel, Direcor, US Patient Services at Shire and Diana Dai, Executive Director, US Pipeline and Launch Management at Sandoz-will shine a light on identifying keys to early commercialization and ensuring post-launch success.
You can receive a $200 discount off this event's registration rate by completing this very short survey:
(Discount expires August 31, 2018).
Advertisement
Related to this article
Brox.AI's co-founder and CEO on why telling an AI to pretend to be a doctor isn’t the same as cloning one — and why that distinction matters for pharma.
Shionogi’s Dr. Draica on why mild COVID-19 still matters, how XOCOVA blocks replication before symptoms, and why prevention beats treatment.
Earlier pediatric planning, innovative trial design, and closer collaboration among regulators, industry, and families are needed to close the persistent gap between the evidence available for adult and pediatric treatments.
BioMarin licenses long-acting Fabry enzyme replacement therapy HM15421/GC1134A, while Ferring agrees to acquire fertility biotech Gameto.
As AI accelerates drug discovery, the industry’s next challenge is building a connected, standards-based data infrastructure capable of supporting it through clinical development.
Shionogi’s Dr. Draica on why mild COVID-19 can worsen chronic conditions for up to a year — and why prevention matters more than hospitalization data suggests.
Brock.AI’s Hamish Brocklebank on recruiting 8% of all US pancreatic cancer prescribers — paying $2,000 an hour, offering equity, and triple opt-in consent.
Advertisement
Advertisement
Trending on PharmExec
1
FDA Approves Ilumya for Adults With Active Psoriatic Arthritis
2
Roundup: BioMarin Licenses Long-Acting Fabry Enzyme Therapy for $70 Million Upfront, Ferring to Acquire Fertility Biotech Gameto in Deal Worth Up to $1.38 Billion
3
Post-Exposure Prophylaxis Is the Missing Piece: Q&A with Florin Draica
4
Evidence With Purpose: Making Real-World Research Better, Not Just Faster
5